About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.
2018 Juristant Badge - MBHB_165
Juristat #4 Overall Rank

E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.

Contact the Docs


  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.
Juristat #8 Overall Rank


« Personalized Media Communications, LLC v. Apple, Inc. (E.D. Tex. 2021) | Main | Chicago Patent Attorneys File Supreme Court Amicus Brief in American Axle »

February 03, 2021


It seems as though Kevin Noonan holds a chunk of Editas stock(or Beam Therapeutics). It is hilarious that Feng Zhang's experiment notes count. Currently, Toolgen has a clear edge over Broad and CVC, for sure. Sorry Dude.

There is a chance that Broad's experiment notes were manipulated.(No offense, don't sue me) Why did they submit their notes in 2020 if they really had it?

I sincerely apologize for offending Mr. Kevin Noonan earlier. I didn't read the very last paragraph. My word about the stock was very inappropriate. You're right. The Board will consider today. I just did not agree with his statement that there is no chance for Toolgen for the patent.
Have a good day.

The comments to this entry are closed.

April 2024

Sun Mon Tue Wed Thu Fri Sat
  1 2 3 4 5 6
7 8 9 10 11 12 13
14 15 16 17 18 19 20
21 22 23 24 25 26 27
28 29 30